** Shares of Sartorius SATG.DE rise 3.6% in early Frankfurt trade after the German pharmaceutical and lab equipment producer posted in-line FY results
** The company reported a revenue of 3.54 billion euros ($4.18 billion) for 2025, meeting analyst expectations of 3.55 billion euros
** Sartorius also gave an outlook for 2026, forecasting sales revenue growth between 5% and 9% and an adjusted EBITDA-margin slightly above 30%
** A local trader says that the outlook was in-line at best and will not satisfy all market participants
** However, the local trader says heavy share price losses in the last days laid the foundation for a potential bounce back in share prices
** The stock is down 2.4% YTD
($1 = 0.8462 euros)
(Reporting by Simon Ferdinand Eibach)
((Simonferdinand.eibach@thomsonreuters.com))